Roivant Sciences Ltd.
36.49USD
-0.9600 (-2.56%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ROIV.
| In $M except per-share | Q1 FY27 | Q4 FY26* | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 3 | 2 | 2 | 2 | 8 | 9 | 4 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -366 | 415 | -339 | -306 | -285 | -285 | -274 | -342 |
| Net Income | -190 | 303 | -266 | -114 | -223 | -206 | 169 | -230 |
| EPS (Diluted) | -$0.26 | $0.34 | -$0.38 | -$0.17 | -$0.33 | -$0.29 | $0.23 | -$0.31 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)